Your browser doesn't support javascript.
loading
Identification of whole-genome mutations and structural variations of bile cell-free DNA in cholangiocarcinoma.
Yin, Lei; Duan, Anqi; Zhang, Wei; Li, Bin; Zhao, Teng; Xu, Xiaoya; Yang, Lixue; Nian, Baoning; Lu, Kai; Chen, Sheng; Li, Zhikuan; Liu, Jian; Duan, Qiaonan; Liu, Dongyu; Chen, Hao; Cui, Longjiu; Chang, Yanxin; Kuang, Yue; Zhang, Dadong; Wang, Xiang; Zhang, Yongjie.
Affiliation
  • Yin L; Department of Biliary Surgery, Eastern Hepatobiliary Surgery Hospital, Naval Medical University (Second Military Medical University), Shanghai, China.
  • Duan A; Department of Biliary Surgery, Eastern Hepatobiliary Surgery Hospital, Naval Medical University (Second Military Medical University), Shanghai, China.
  • Zhang W; Department of Clinical and Translational Medicine, 3D Medicines Inc., Shanghai, China.
  • Li B; Department of Clinical and Translational Medicine, 3D Medicines Inc., Shanghai, China.
  • Zhao T; Department of Biliary Surgery, Eastern Hepatobiliary Surgery Hospital, Naval Medical University (Second Military Medical University), Shanghai, China.
  • Xu X; Department of Clinical and Translational Medicine, 3D Medicines Inc., Shanghai, China.
  • Yang L; Department of Biliary Surgery, Eastern Hepatobiliary Surgery Hospital, Naval Medical University (Second Military Medical University), Shanghai, China.
  • Nian B; Department of Clinical and Translational Medicine, 3D Medicines Inc., Shanghai, China.
  • Lu K; Department of Biliary Surgery, Eastern Hepatobiliary Surgery Hospital, Naval Medical University (Second Military Medical University), Shanghai, China.
  • Chen S; Department of Clinical and Translational Medicine, 3D Medicines Inc., Shanghai, China.
  • Li Z; Department of Clinical and Translational Medicine, 3D Medicines Inc., Shanghai, China.
  • Liu J; Department of Biliary Surgery, Eastern Hepatobiliary Surgery Hospital, Naval Medical University (Second Military Medical University), Shanghai, China.
  • Duan Q; Department of Clinical and Translational Medicine, 3D Medicines Inc., Shanghai, China.
  • Liu D; Department of Clinical and Translational Medicine, 3D Medicines Inc., Shanghai, China.
  • Chen H; Department of Clinical and Translational Medicine, 3D Medicines Inc., Shanghai, China.
  • Cui L; Department of Biliary Surgery, Eastern Hepatobiliary Surgery Hospital, Naval Medical University (Second Military Medical University), Shanghai, China.
  • Chang Y; Department of Biliary Surgery, Eastern Hepatobiliary Surgery Hospital, Naval Medical University (Second Military Medical University), Shanghai, China.
  • Kuang Y; Department of Biliary Surgery, Eastern Hepatobiliary Surgery Hospital, Naval Medical University (Second Military Medical University), Shanghai, China.
  • Zhang D; Department of Clinical and Translational Medicine, 3D Medicines Inc., Shanghai, China. Electronic address: dadong.zhang@3dmedcare.com.
  • Wang X; Department of Biliary Surgery, Eastern Hepatobiliary Surgery Hospital, Naval Medical University (Second Military Medical University), Shanghai, China. Electronic address: drwangxiang@hotmail.com.
  • Zhang Y; Department of Biliary Surgery, Eastern Hepatobiliary Surgery Hospital, Naval Medical University (Second Military Medical University), Shanghai, China. Electronic address: zhangyj_official@163.com.
Genomics ; : 110916, 2024 Aug 13.
Article in En | MEDLINE | ID: mdl-39147332
ABSTRACT
Bile cell-free DNA (cfDNA) has been reported as a promising liquid biopsy tool for cholangiocarcinoma (CCA), however, the whole-genome mutation landscape and structural variants (SVs) of bile cfDNA remains unknown. Here we performed whole-genome sequencing on bile cfDNA and analyzed the correlation between mutation characteristics of bile cfDNA and clinical prognosis. TP53 and KRAS were the most frequently mutated genes, and the RTK/RAS, homologous recombination (HR), and HIPPO were top three pathways containing most gene mutations. Ten overlapping putative driver genes were found in bile cfDNA and tumor tissue. SVs such as chromothripsis and kataegis were identified. Moreover, the hazard ratio of HR pathway mutations were 15.77 (95% CI 1.571-158.4), patients with HR pathway mutations in bile cfDNA exhibited poorer overall survival (P = 0.0049). Our study suggests that bile cfDNA contains genome mutations and SVs, and HR pathway mutations in bile cfDNA can predict poor outcomes of CCA patients.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Genomics Journal subject: GENETICA Year: 2024 Type: Article Affiliation country: China

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Genomics Journal subject: GENETICA Year: 2024 Type: Article Affiliation country: China